Regulating Innovation: How Policy is Reshaping the Future of Health
David Farber, Partner at King & Spalding, joins host Gil Bashe, Chair, Global Health and Purpose at FINN Partners, for a Global Health and Purpose Summit discussion on the leadership realities that determine whether health innovation can move from scientific and technological promise into practical patient access.
Health innovation is shaped not only by what science can create, but by how effectively the healthcare system can evaluate new technologies, finance their adoption, measure outcomes, and deliver them responsibly to clinicians and patients. In this context, regulation and reimbursement are not peripheral issues for innovators. They are core leadership disciplines that shape market access, investment confidence, and the speed with which better care reaches the people who need it.
Farber connects CMS, FDA, CMMI, reimbursement frameworks, payer dynamics, program integrity, and evidence requirements to the real-world pathway for new treatments, devices, digital tools, and care models. His perspective places policy inside the innovation model, where decisions about payment, outcomes, coverage, and access need to be considered early in product strategy.
The session moves from strategy to implementation through the AHEAD model, the RAPID effort to improve coordination between device review and coverage, and the payer dynamics that influence adoption beyond Medicare, while Bashe brings the topic into everyday care delivery through smart embedded technologies, wearables, patient-provider communication tools, and ambient documentation that can reduce friction and help clinicians focus more directly on patients.
The next generation of health leadership will belong to organizations that align scientific ambition with evidence, reimbursement discipline, implementation readiness, and an unwavering commitment to patient benefit.
Session Intelligence
Policy, reimbursement, evidence, payer behavior, and outcome-based models form the operating environment that determines whether new technologies can move from development to patient access.
Innovation Pathways
CMS, FDA, CMMI, payer dynamics, and reimbursement frameworks influence how new technologies reach patients.
Outcome-Based Models
AHEAD and CMMI-style models show growing interest in technology adoption connected to measurable health outcomes.
Breakthrough Devices
RAPID reflects the continuing effort to improve coordination between device review and coverage pathways.
Patient Access
Digital tools, remote monitoring, and embedded technologies can help care teams connect innovation to real patient benefit.
Information
Languages
Accessibility
